Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Apheresis‐Triggered Torsades De Pointes in Congenital Long QT Syndrome Type 2: Citrate‐Related Arrhythmia Risk and Safe Modality Switching During Myasthenic Crisis. Local targets link to admitted publications; unresolved targets remain external evidence.
Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation
10.1016/j.jacc.2010.01.001 · 2010 · External reference
Alcoholic Liver Cirrhosis Complicated With Torsade de Pointes During Plasma Exchange and Hemodiafiltration
10.1007/s005350170061 · 2001 · External reference
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Ninth Special Issue
10.1002/jca.22043 · 2023 · External reference
MuSK Antibody Clearance During Serial Sessions of Plasmapheresis for Myasthenia Gravis
10.1016/j.jns.2007.05.033 · 2007 · External reference
Anti‐MuSK Antibody Myasthenia Gravis: Clinical Findings and Response to Treatment in Two Large Cohorts
10.1002/mus.22006 · 2011 · External reference
Safety, Efficacy, and Tolerability of Efgartigimod in Patients With Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo‐Controlled, Phase 3 Trial
10.1016/s1474-4422(21)00159-9 · 2021 · External reference
